VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company’s existing Nu.Q NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.
Volition said its CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. The company is seeking partnerships with global health organizations, pharmaceutical developers, NGOs and distribution partners to support field trials, manufacturing scale-up and potential deployment in outbreak zones. The full press release is available at https://ibn.fm/UOWP1.
Volition is a multi-national company focused on advancing the science of epigenetics. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
The Ebola virus disease (EVD) remains a significant public health threat in parts of Africa, with sporadic outbreaks causing high mortality rates. Rapid triage and diagnosis are critical for controlling outbreaks and providing timely care. Volition’s Nu.Q technology offers a novel approach that could be deployed in field settings without the need for sophisticated laboratory infrastructure. The finger-prick lateral flow test, in particular, could enable healthcare workers to quickly assess patients and prioritize those requiring urgent treatment or isolation.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. More information about the company can be found at https://volition.com/.
The patent application underscores Volition’s commitment to expanding its intellectual property portfolio and addressing global health challenges. If successful, the technology could complement existing diagnostic tools and strengthen outbreak response capabilities. The company is actively engaging potential partners to advance the product through field trials and regulatory approvals.
